Patient-related post-ERCP pancreatitis (PEP) risk factors between two groups of patients: Prophylactic pancreatic stent and rectal indomethacin
Background: Pancreatitis is one of the most crucial complications following endoscopic retrograde cholangiopancreatography (ERCP). The purpose of the current study was to investigate patient-related post-ERCP pancreatitis (PEP) risk factors in two groups of patients: prophylactic pancreatic stent an...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Babol University of Medical Sciences
2022-09-01
|
| Series: | Caspian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | http://caspjim.com/article-1-3033-en.html |
| _version_ | 1811255741399433216 |
|---|---|
| author | Hossein Ghalehnoei Ahmad Hormati Amir Houshang Mohammad Alizadeh Sajjad Ahmadpour Seyed Hassan Abedi |
| author_facet | Hossein Ghalehnoei Ahmad Hormati Amir Houshang Mohammad Alizadeh Sajjad Ahmadpour Seyed Hassan Abedi |
| author_sort | Hossein Ghalehnoei |
| collection | DOAJ |
| description | Background: Pancreatitis is one of the most crucial complications following endoscopic retrograde cholangiopancreatography (ERCP). The purpose of the current study was to investigate patient-related post-ERCP pancreatitis (PEP) risk factors in two groups of patients: prophylactic pancreatic stent and rectal indomethacin.
Methods: Two different prophylactic modalities were planned and complications were assessed based on the defined inclusion criteria. In this study, the patients were evaluated for the procedure and patient-related risk factors in post-ERCP pancreatitis in the recipient groups of the prophylactic pancreatic stent and rectal indomethacin.
Results: Pancreatitis was confirmed in 27 of all 170 selected patients after ERCP. By univariate analysis, two variables were significant with the development of PEP. Regarding the patient-related risk factors, unique subjects with common bile duct (CBD) dilated 10mm were more exposed to an increased chance of PEP (P=0. 015); meanwhile, other factors did not correlate with the increased possibility of PEP in both groups. The only procedure-related risk factor for PEP was the deep cannulation of the pancreatic duct in both groups during the procedure with an incremental significant incidence of pancreatitis (P=0.005). Comparison of prophylactic pancreatic stent and rectal indomethacin showed no effects in term of post ERCP pancreatitis reduction. Additionally, there was no significant difference between these two strategies in the rate of PEP.
Conclusion: Prophylactic pancreatic duct stents and administration of rectal indomethacin cannot have particular approaches for reducing the possible occurrence of PEP. The increase in time of deep cannulation and the presence of CBD dilation <10mm could be considered as important risk factors. |
| first_indexed | 2024-04-12T17:28:19Z |
| format | Article |
| id | doaj.art-94ff6e32c090460da048c8f6b2df5050 |
| institution | Directory Open Access Journal |
| issn | 2008-6164 2008-6172 |
| language | English |
| last_indexed | 2024-04-12T17:28:19Z |
| publishDate | 2022-09-01 |
| publisher | Babol University of Medical Sciences |
| record_format | Article |
| series | Caspian Journal of Internal Medicine |
| spelling | doaj.art-94ff6e32c090460da048c8f6b2df50502022-12-22T03:23:12ZengBabol University of Medical SciencesCaspian Journal of Internal Medicine2008-61642008-61722022-09-01134728734Patient-related post-ERCP pancreatitis (PEP) risk factors between two groups of patients: Prophylactic pancreatic stent and rectal indomethacinHossein Ghalehnoei0Ahmad Hormati1Amir Houshang Mohammad Alizadeh2Sajjad Ahmadpour3Seyed Hassan Abedi4 Department of Medical Biotechnology, Molecular, and Cell Biology Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol Iran Background: Pancreatitis is one of the most crucial complications following endoscopic retrograde cholangiopancreatography (ERCP). The purpose of the current study was to investigate patient-related post-ERCP pancreatitis (PEP) risk factors in two groups of patients: prophylactic pancreatic stent and rectal indomethacin. Methods: Two different prophylactic modalities were planned and complications were assessed based on the defined inclusion criteria. In this study, the patients were evaluated for the procedure and patient-related risk factors in post-ERCP pancreatitis in the recipient groups of the prophylactic pancreatic stent and rectal indomethacin. Results: Pancreatitis was confirmed in 27 of all 170 selected patients after ERCP. By univariate analysis, two variables were significant with the development of PEP. Regarding the patient-related risk factors, unique subjects with common bile duct (CBD) dilated 10mm were more exposed to an increased chance of PEP (P=0. 015); meanwhile, other factors did not correlate with the increased possibility of PEP in both groups. The only procedure-related risk factor for PEP was the deep cannulation of the pancreatic duct in both groups during the procedure with an incremental significant incidence of pancreatitis (P=0.005). Comparison of prophylactic pancreatic stent and rectal indomethacin showed no effects in term of post ERCP pancreatitis reduction. Additionally, there was no significant difference between these two strategies in the rate of PEP. Conclusion: Prophylactic pancreatic duct stents and administration of rectal indomethacin cannot have particular approaches for reducing the possible occurrence of PEP. The increase in time of deep cannulation and the presence of CBD dilation <10mm could be considered as important risk factors.http://caspjim.com/article-1-3033-en.htmlercppost ercp pancreatitispancreatic duct stentrectal indomethacin |
| spellingShingle | Hossein Ghalehnoei Ahmad Hormati Amir Houshang Mohammad Alizadeh Sajjad Ahmadpour Seyed Hassan Abedi Patient-related post-ERCP pancreatitis (PEP) risk factors between two groups of patients: Prophylactic pancreatic stent and rectal indomethacin Caspian Journal of Internal Medicine ercp post ercp pancreatitis pancreatic duct stent rectal indomethacin |
| title | Patient-related post-ERCP pancreatitis (PEP) risk factors between two groups of patients: Prophylactic pancreatic stent and rectal indomethacin |
| title_full | Patient-related post-ERCP pancreatitis (PEP) risk factors between two groups of patients: Prophylactic pancreatic stent and rectal indomethacin |
| title_fullStr | Patient-related post-ERCP pancreatitis (PEP) risk factors between two groups of patients: Prophylactic pancreatic stent and rectal indomethacin |
| title_full_unstemmed | Patient-related post-ERCP pancreatitis (PEP) risk factors between two groups of patients: Prophylactic pancreatic stent and rectal indomethacin |
| title_short | Patient-related post-ERCP pancreatitis (PEP) risk factors between two groups of patients: Prophylactic pancreatic stent and rectal indomethacin |
| title_sort | patient related post ercp pancreatitis pep risk factors between two groups of patients prophylactic pancreatic stent and rectal indomethacin |
| topic | ercp post ercp pancreatitis pancreatic duct stent rectal indomethacin |
| url | http://caspjim.com/article-1-3033-en.html |
| work_keys_str_mv | AT hosseinghalehnoei patientrelatedpostercppancreatitispepriskfactorsbetweentwogroupsofpatientsprophylacticpancreaticstentandrectalindomethacin AT ahmadhormati patientrelatedpostercppancreatitispepriskfactorsbetweentwogroupsofpatientsprophylacticpancreaticstentandrectalindomethacin AT amirhoushangmohammadalizadeh patientrelatedpostercppancreatitispepriskfactorsbetweentwogroupsofpatientsprophylacticpancreaticstentandrectalindomethacin AT sajjadahmadpour patientrelatedpostercppancreatitispepriskfactorsbetweentwogroupsofpatientsprophylacticpancreaticstentandrectalindomethacin AT seyedhassanabedi patientrelatedpostercppancreatitispepriskfactorsbetweentwogroupsofpatientsprophylacticpancreaticstentandrectalindomethacin |